Articolul precedent |
Articolul urmator |
390 3 |
Ultima descărcare din IBN: 2023-09-15 14:19 |
SM ISO690:2012 ROȘCA, Ana, GUDUMAC, Eva. Efectul tratamentului cu somatostatină/ octreotidă la nounăscuții cu chilotorax congenital. In: Congresul consacrat aniversării a 75-a de la fondarea Universității de Stat de Medicină şi Farmacie „Nicolae Testemiţanu”, 21-23 octombrie 2020, Chişinău. Chişinău: USMF, 2020, p. 618. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Congresul consacrat aniversării a 75-a de la fondarea Universității de Stat de Medicină şi Farmacie „Nicolae Testemiţanu” 2020 | ||||||
Congresul "Congresul consacrat aniversării a 75-a de la fondarea Universității de Stat de Medicină şi Farmacie „Nicolae Testemiţanu”" Chişinău, Moldova, 21-23 octombrie 2020 | ||||||
|
||||||
Pag. 618-618 | ||||||
|
||||||
Descarcă PDF | ||||||
Rezumat | ||||||
Background. Chylothorax is a pleural effusion secondary to the accumulation of lymphatic fluid in the pleura, having a multifactorial etiology, including idiopathic called congenital chylothorax. The reported incidence of congenital chylothorax is about 1:5800 to 1:24000 in live-born neonates. Objective of the study. The purpose of this study was to evaluate the efficacy and safety of somatostatin/octreotide treatment in patients with congenital chylothorax. Material and Methods. The study was performed on a group of 14 newborns with congenital chylothorax. Pleural effusion in children was considered a chyle when it contained >1.1 mmol/L triglycerides and a total cell count >1000 cells/mL. The volumes of pleural drainage before and after treatment were compared by a paired t test. P values <0.05 were considered statistically significant. Results. Somatostatin/octreotide was started at a median of 4 days (range 1–13 days) after chest tube insertion, and maintained for a median period of 6 days (range 1–16 days). The drainage volume in the first day after treatment was significantly lower than that in the day before treatment (median 70 mL, range5–651 mL vs median 150 mL, range 80–630 mL) (P = 0.001). Subsequently, the drainage was stabilized and gradually decreased in most patients until less than 10 mL/kg/d. The need for respiratory support decreased in most patients (85.7%, 12/14) after the initiation of somatostatin/octreotide. Conclusion. In this group of neonates with congenital chylothorax, somatostatin/octreotide treatment reduced the volume of pleural drainage and the need for respiratory support, without side effects. The hospital survival was 85.7%, and no late recurrent chylothorax occurred. |
||||||
Cuvinte-cheie Congenital chylothorax, neonates, octreotide, somatostatin, chilotorax congenital, nou-născuți, octreotidă, somatostatină |
||||||
|